Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
solid tumor
Biotech
Merck pays $588M for bispecific to defend Keytruda’s kingdom
The outlay, plus up to $2.7 billion in milestones, has secured Merck global rights to LaNova Medicines’ PD-1xVEGF bispecific antibody.
Nick Paul Taylor
Nov 14, 2024 7:45am
BioNTech pays $800M to take control of potential Keytruda killer
Nov 13, 2024 6:45am
Alentis raises $181M series D to bring ADCs to the clinic
Nov 12, 2024 7:00am
Carisma's Moderna-powered cell therapy shrinks tumors in mice
Nov 8, 2024 7:30am
Allogene links solid tumor CAR-T to responses, deaths in phase 1
Nov 8, 2024 4:47am
ADC Therapeutics axes lead solid tumor drug after phase 1 blow
Nov 7, 2024 8:24am
